Interesterified palm olein lowers postprandial glucose-dependent insulinotropic polypeptide response in type 2 diabetes.

What Was Tested

This randomized controlled trial looks at GIP (Gastric Inhibitory Polypeptide).

The researchers aim to investigate the postprandial effects of palm olein (PO) and chemically interesterified palm olein (IPO) with different proportions of palmitic acid at the sn-2 position using high oleic sunflower oil (HOS) as control fat on concentrations of gut hormones, glucose homeostasis, satiety, lipid and inflammatory parameters in type 2 diabetic (T2D) subjects.

Who Took Part

According to the abstract, 6, women were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the women nor the staff measuring them knew who was on GIP (Gastric Inhibitory Polypeptide), so expectations could not easily colour the readings.

In the crossover set-up each of the women took both GIP (Gastric Inhibitory Polypeptide) and the comparison in turn, acting as their own control.

Postprandial changes in gut hormones, glucose homeostasis, satiety, lipid and inflammatory parameters after meals were analysed.

Some of the solid fractions of the IPO were removed and thus the fatty acid composition of the PO and IPO was not entirely equal (PO vs IPO: palmitate 39.8 vs 38.7; oleate 43.6 vs 45.1).

What Was Measured

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Inflammation, Lipids, Palm Oil and Postprandial Period.

Author keywords: Glucose metabolism, Glucose-dependent insulinotropic polypeptide, Gut hormones, Interesterified palm olein and Type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of GIP (Gastric Inhibitory Polypeptide) in 6, women.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (European journal of nutrition), a journal based in Germany.

More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.